Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Affirm Holdings Inc (AFRM) vs GeneDx Holdings Corp (WGS) Price & Performance

Affirm Holdings IncTrade
GeneDx Holdings CorpTrade

Price performance (Past 24H)

Key statistics

Affirm Holdings Inc vs GeneDx Holdings Corp — how do they compare? Affirm Holdings Inc trades at $77 (market cap $25.30B), while GeneDx Holdings Corp trades at $81.74 (market cap $2.32B). The key difference: Affirm Holdings Inc is far larger — about 10.9× GeneDx Holdings Corp's market cap, and Affirm Holdings Inc is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.

AFRMWGS
Market Cap
$25.30B$2.32B
Sector
FinancialsTechnology
52-Week High
$92.18$167.51
52-Week Low
$42.53$34.51
Enterprise Value
$31.91B$2.35B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Affirm Holdings Inc

AFRM trades at $75.25, down 1.74% on the day, with a bullish technical signal supported by moving averages. The company reported strong revenue growth to $3.22B in 2025, turning profitable with net income of $52.19M, and has beaten EPS estimates in recent quarters. Positive sentiment is driven by analyst optimism and expanding merchant partnerships.

Outlook remains favorable with a consensus price target of $96.00, indicating 28% upside. Risks include high valuation multiples (P/E 68.41) and sensitivity to interest rate changes. Continued execution on growth and profitability will be key for stock performance.

GeneDx Holdings Corp

GeneDx Holdings Corp. (WGS) trades at $77.08, up 10.76% today, showing strong momentum despite negative profitability metrics. The stock exhibits bullish technical signals with support at $72 and resistance at $80. Recent Q2 2026 earnings beat expectations with $0.01 EPS versus -$0.19 estimate, while revenue reached $114.4 million. However, the company faces significant challenges with a -23.4% net income margin and ongoing securities class action litigation.

Investment outlook remains cautiously optimistic given strong analyst support (90.9% buy rating) and $79.25 consensus price target. Key opportunities include growing genomic testing volumes and improved operational efficiency, while risks center on profitability challenges, legal liabilities, and high valuation multiples that may not justify current fundamentals.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Affirm Holdings Inc

Affirm Holdings Inc offers a platform for digital and mobile first commerce. It comprises a point-of-sale payment solution for consumers, merchant commerce solutions, and a consumer-focused app. The firm generates its revenue from merchant networks, and through virtual card networks among others. Geographically, it generates a major share of its revenue from the United States.

Read more on AFRM

About GeneDx Holdings Corp

GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.

Read more on WGS